Publications 2012

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, et al. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS. 24 août 2012;26(13):1691‑705. Disponible sur:

Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, et al. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol. avr 2012;41(2):433‑45. Disponible sur:

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, et al. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis. 1 mai 2012;54(9):1364‑72. Disponible sur:

Guiguet M, Ghosn J, Duvivier C, Meynard J-L, Gras G, Partisani M, et al. Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study. AIDS. 28 nov 2012;26(18):2345‑50. Disponible sur:

Jarrin I, Pantazis N, Gill MJ, Geskus R, Perez-Hoyos S, Meyer L, et al. Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis. 1 janv 2012;54(1):111‑8. Disponible sur:

Jarzebowski W, Caumes E, Dupin N, Farhi D, Lascaux A-S, Piketty C, et al. Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort. Arch Intern Med. 10 sept 2012;172(16):1237‑43. Disponible sur:

Lang S, Mary-Krause M, Simon A, Partisani M, Gilquin J, Cotte L, et al. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis. 15 août 2012;55(4):600‑7. Disponible sur:

Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med. 10 sept 2012;172(16):1252‑5. Disponible sur:

May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, et al. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol. déc 2012;41(6):1807‑20. Disponible sur:

Murray M, Hogg RS, Lima VD, May MT, Moore DM, Abgrall S, et al. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Med. févr 2012;13(2):89‑97. Disponible sur:

Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, et al. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med. 2012;9(3):e1001194. Disponible sur:

Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, et al. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS One. 6 mars 2012;7(3):e32369. Disponible sur:

Piketty C, Selinger-Leneman H, Bouvier A-M, Belot A, Mary-Krause M, Duvivier C, et al. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. J Clin Oncol. 10 déc 2012;30(35):4360‑6. Disponible sur:

Pursuing Later Treatment Option II (PLATO II) project team, Observational HIV Epidemiological Research Europe (COHERE) Group, Costagliola D, Lodwick R, Ledergerber B, Torti C, et al. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis. févr 2012;12(2):119‑27. Disponible sur:

Pursuing Later Treatment Options II (PLATO II) project team, Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group, Nakagawa F, Lodwick R, Costagliola D, van Sighem A, et al. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. J Acquir Immune Defic Syndr. 1 mars 2012;59(3):294‑9. Disponible sur:

Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, et al. Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection. Antivir Ther. 2012;17(6):1039‑48. Disponible sur: